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IL-25 Induces IL-4, IL-5, and IL-13
and Th2-Associated Pathologies In Vivo
quent investigations have shown that some cytokines
within a given family may play unique roles in the genera-
tion of innate or acquired immune responses. IL-25 is
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Satish Menon,1 Teresa Clifford,1 Brisdell Hunte,1
Robin Lesley,1 Tony Muchamuel,1 Stephen D. Hurst,1 structurally related to IL-17, and the human sequence
has recently been described (Lee et al., 2000). Our stud-Gerard Zurawski,1 Michael W. Leach,2
Daniel M. Gorman,1 and Donna M. Rennick1,3 ies show that the in vivo and in vitro biological activities
of IL-25 are markedly different from those described for1 DNAX Research Institute
Palo Alto, California 94304 IL-17 and other IL-17-related family members. Treat-
ment of mice with purified IL-25 resulted in the produc-2 Schering-Plough Research Institute
Lafayette, New Jersey 07848 tion of cytokines IL-4, IL-5, and IL-13, eosinophilia, in-
creased serum Ig, and the development of striking
histological changes in the lungs and the gastrointesti-
nal (GI) tract.Summary
We have characterized a cytokine produced by Th2
Resultscells, designated as IL-25. Infusion of mice with IL-25
induced IL-4, IL-5, and IL-13 gene expression. The
Identification of IL-25induction of these cytokines resulted in Th2-like re-
Using IL-17 and other family members for bait, we per-sponses marked by increased serum IgE, IgG1, and IgA
formed a BLAST search against the NCBI EST databaselevels, blood eosinophilia, and pathological changes in
and identified a unique mouse EST (IMAGE clonethe lungs and digestive tract that included eosinophilic
419419) with significant sequence homology to IL-17.infiltrates, increased mucus production, and epithelial
Full-length cloning of the mouse cDNA and human or-cell hyperplasia/hypertrophy. In addition, our studies
tholog revealed ORFs encoding 169 and 161 residuesshow that IL-25 induces Th2-type cytokine production
for mouse and human, respectively. Analysis of theseby accessory cells that are MHC class IIhigh, CD11cdull,
protein sequences identified the following overall con-and lineage. These results suggest that IL-25, derived
served characteristics: an N-terminal leader sequence,from Th2 T cells, is capable of amplifying allergic type
a single potential N-linked glycosylation site, and calcu-inflammatory responses by its actions on other cell
lated mature molecular weights of 17.5 (mouse) and 16.7types.
kDa (human). The mouse and human proteins have 10
conserved cysteine residues (11 total in the mouse) andIntroduction
are 80% identical (Figure 1).
We have identified a cytokine (IL-25) that is structurally
related to IL-17. (The interleukin-25 designation has
Expression Analysis of IL-25been approved by the IUIS Subcommittee on Interleukin
We examined various mouse cell lines and tissues forNomenclature.) Other cytokines with structural homol-
IL-25 gene expression, using a highly sensitive, quantita-ogy to IL-17 have been identified as IL-17B and IL-17C
tive PCR method. Analysis of a panel of cDNA libraries(Li et al., 2000; Shi et al., 2000). Preliminary in vitro and
showed that only cDNA libraries made from T cells thatin vivo data suggest that IL-17, IL-17B, and IL-17C have
had been stimulated for 7 days or for 3 weeks (“highlyoverlapping, albeit not identical, biological activities. For
polarized”) in the presence of IL-4/anti-IL-12 mAb hadexample, IL-17 induces the production of other cyto-
detectable IL-25 gene expression (Figure 2A). To confirmkines and inflammatory mediators, including IL-1, IL-6,
these results, naive CD4 T cells were isolated fromIL-8, and TNF, from a variety of cells (Fossiez et al.,
BALB/c, B6, and 129 SvEv mice and polarized for 71998; Jovanovic et al., 1998). IL-17B and IL-17C are
days in vitro in Th2-polarizing conditions (IL-4/anti-IL-12able to induce the production of TNF and IL-1 by
mAb/anti-IFN mAb). The expression of IL-25 mRNAa monocytic cell line (Li et al., 2000). Although gene
was detected in Th2-polarized T cells from all mouseexpression studies indicate that the cellular sources of
strains, but not from freshly isolated naive CD4 T cellsIL-17, IL-17B, and IL-17C may not be identical, their
(data not shown), which confirmed the results from theactions in vivo are similar (Li et al., 2000; Shi et al., 2000).
cDNA library panel. Despite its association with Th2Treatment of mice with IL-17 or IL-17B protein results
cells, IL-25 mRNA expression was not detectable in thein a similar phenotype, typified by neutrophil infiltration
spleens of wild-type (WT) mice (Figure 2B). Low levelsinto tissue (Shi et al., 2000).
of IL-25 mRNA expression were found in various tissuesAlthough proinflammatory cytokines may be grouped
(Figure 2B), with the highest expression in the GI tractinto families based on structural homologies, subse-
and the uterus. As T cells can be found throughout the
entire GI tract and other mucosal tissues, activated Th23 Correspondence: rennick@dnax.org
cells within those tissues may be the source of IL-254 These authors contributed equally to this work.
mRNA. However, it remains possible that other cell types5 Present address: Corixa Corporation, 600 Gateway Boulevard,
South San Francisco, California 94080. may express the IL-25 gene as well.
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Figure 1. Alignment of Amino Acid Sequences of Mouse and Human IL-25
Human and mouse IL-25 protein sequences were aligned using ClustalX. The predicted leader cleavage site is marked with an arrow. The
predicted N-linked glycosylation site is marked with “^”. Conserved and identical residues are indicated by “:” and “*”, respectively. An amino
acid coloring scheme correlates chemically similar residues as follows: green (hydrophobic), red (acidic), blue (basic), yellow (C), orange
(aromatic), black (structure breaking), purple (amido), and gray (small).
IL-25 Protein Treatment of Mice Induces response to IL-25 treatment, mice were given 0.1–10 g
IL-25 daily, and blood samples were taken at variousSplenomegaly, Eosinophilia, and Serum IgE
To gain a better understanding of the biological role of time points. As seen in Figure 3C, as little as 0.1 g
IL-25 caused eosinophilia in the peripheral blood by dayIL-25 in vivo, we injected WT mice intraperitoneally (i.p.)
with purified IL-25 protein or saline and monitored the 4 of treatment. The blood eosinophilia reached a peak
at day 7 at all doses of IL-25 given. The absolute numbermice for changes in hematopoietic parameters. Mice
treated daily with 10 g of IL-25 for 10 days developed of peripheral blood neutrophils was unaffected by IL-25
at any dose or time point (Figure 3C). These data showsplenomegaly with significantly higher numbers of eo-
sinophils but not neutrophils (Figures 3A and 3B). The that IL-25 can induce the mobilization of eosinophils into
the blood. Importantly, these hematopoietic changes innumber of splenic plasma cells was also increased (Fig-
ure 3B). In addition, spleens from IL-25-treated mice response to IL-25 treatment were seen in three different
strains of WT mice (C57BL/6, BALB/c, and 129 SvEv),had a 20-fold higher number of myeloid colony forming
cells (CFU-c) as compared to control spleens, indicating and these data indicate that observed immunologic
changes were not due to a strain-specific effect of IL-25a mobilization of hematopoietic progenitor cells to the
spleens of IL-25-treated animals (data not shown). The (data not shown).
Th2-type inflammatory responses are characterizedincreased numbers of splenic eosinophils were mirrored
by an increase in eosinophils in the blood. To determine by recruitment of eosinophils as well as increased serum
IgE and IgG1 (Romagnani, 1992). Therefore, we evalu-the dose and time course of the eosinophilia seen in
Figure 2. Gene Expression of IL-25 in Various Cell Lines and Tissues
(A) The relative mRNA expression of IL-25 in 20 ng of cDNA from various cell line libraries.
(B) The relative mRNA expression of IL-25 in 50 ng of cDNA from tissues from BALB/c mice. Tissues were taken from four mice per group,
and the amount of IL-25 mRNA was quantified for each individual tissue, except for Peyer’s Patches, which were pooled due to the small
amount of tissue.
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Figure 3. In Vivo Treatment with IL-25 Protein
Results in Splenomegaly and Eosinophilia
(A and B) C57BL/6 mice (n  4 per group)
were injected i.p. daily, starting on day 1, with
saline or 10 g IL-25 for 10 days. Spleens
were harvested, weighed, and then made into
single-cell suspensions to determine total cel-
lularity. Relative populations were determined
microscopically with Wright’s-Giemsa-stained
cytospins.
(C) C57BL/6 mice were treated for 10 days
with varying doses of IL-25 or with saline (n
5 per group). At days 2, 4, 7, and 10, blood
samples were taken for total white blood cell
count, and the relative populations were enu-
merated from blood smears stained with
Wright’s-Giemsa. (*, p  0.05)
ated circulating Ig levels in mice receiving IL-25 (Figure intestine, kidney, liver, lung, and colon (Figure 5A and
data not shown). The mRNA expression of both IL-4 and4). Mice treated daily with 5 g IL-25 had significantly
higher serum IgE and IgG1. Interestingly, circulating IgA IL-5 was significantly higher in the spleens of IL-25-
treated mice, but varied in other tissues. We also exam-was greatly increased in IL-25-treated animals (Figure
4). In addition, the amount of IgA in the intestinal con- ined the gene expression of other cytokines and chemo-
kines. The spleen, stomach, and small intestine of IL-25-tents was higher with IL-25 treatment (2.66 	 0.46 g/
ml versus 6.89 	 0.75 g/ml in saline-treated versus treated mice had significantly increased expression of
IL-6 and eotaxin when compared to tissues from saline-IL-25-treated mice, respectively; p  0.0014).
treated mice (data not shown). There was no change in
the gene expression of IL-1, TNF, IL-10, or IFN withIL-25 Induces Gene Expression
of Th2-Associated Cytokines IL-25 treatment (data not shown). Moreover, there was
no increase in IL-25 mRNA expression in mice treatedIncreased circulating and infiltrating eosinophils are as-
sociated with the production of IL-5, while IgE, IgG1, and with IL-25, suggesting IL-25 does not induce its own
gene expression (data not shown). Together these dataIgA synthesis are associated with IL-4 and IL-13 (Bost
et al., 1996; Chomarat and Banchereau, 1998; Roboz indicate that IL-25 treatment preferentially induces the
gene expression of Th2-associated cytokines.and Rafii, 1999). Therefore, we tested whether IL-25 treat-
ment might induce the expression of Th2-associated To confirm that IL-25 could induce the production of
Th2 cytokines, we tested the ability of IL-25 to stimulatecytokines in vivo. Total RNA was isolated from various
tissues from mice treated for 10 days with either saline the production of IL-4, IL-5, and/or IL-13 in vitro. When
CD4CD45RBhigh (“naive”) or CD4CD45RBlow (“mem-or 10 g IL-25 and then tested for the presence of IL-4,
IL-5, and IL-13 mRNA by quantitative PCR analysis. IL-25 ory”) T cells were stimulated with anti-CD3/anti-CD28
mAbs in the presence of IL-25, the production of IL-4,treatment strongly induced the gene expression of IL-13
in all tissues tested, including the spleen, stomach, small IL-5, and IL-13 by these cells was unaffected (data not
Figure 4. IL-25 Induces an Increase in Serum
IgG1, IgA, and IgE
C57BL/6 mice (n 4 per group) were injected
daily i.p. with either saline or 5 g/day of IL-
25 protein for 10 days. Blood was collected
on day 10 to determine serum isotype levels
by sandwich ELISA. Results shown are repre-
sentative of two independent experiments. (*,
p  0.05)
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Figure 5. IL-25 Induces IL-4, IL-5, and IL-13
Gene Expression and Protein Production
from a Nonlymphoid Accessory Cell
(A) C57BL/6 mice (n  3–5 per group) were
treated daily with 10 g IL-25 or saline for 10
days and then organs were harvested. Total
RNA was isolated from individual tissues, and
the amount of IL-4, IL-5, and IL-13 mRNA was
quantified by PCR as described in Experi-
mental Procedures. The results shown are
typical of three independent experiments. (*,
p  0.05; **, p  0.01)
(B) Unfractionated splenocytes from C57BL/6
mice (WT), T and B cell-depleted splenocytes
from WT mice (T & B cell depleted) and RAG
KO mice were cultured in the presence or
absence of optimal concentrations of IL-25
(10–50 ng/ml) as described in Experimental
Procedures. Splenocytes from RAG KO mice
treated with IL-25 were depleted of CD11b,
Gr-1, B220, and CD4 cells (CD11bGr-
1B220CD4) or sorted for high or low ex-
pression of MHC class II (RAG KO class II low;
RAG KO class II high) and were cultured in the
presence of optimal concentrations of IL-25.
Cell-free supernatants were assayed for IL-13
by sandwich ELISA. The results shown are
typical of two to four independent experi-
ments.
(C) RAG KO mice were treated with 5 g/
mouse IL-25 for 4–5 days, and MHC class
IIhigh expressing cells were sorted from their
spleens (
95% purity). Sorted cells were then
analyzed by FACS for expression of CD11c
and CD8. Green line denotes isotype control
staining.
shown). Furthermore, IL-25 did not induce IL-4 produc- To further characterize which non-T/non-B cells may
be producing IL-5 and/or IL-13 in response to IL-25 intion by purified CD19CD11b or CD19CD11b B cells
stimulated in the presence of LPS and/or anti-CD40 vitro, we examined various cell types present in the
spleens of RAG KO mice. Purified monocytes (CD11bmAb. When unfractionated splenocytes from WT mice
were cultured in the presence of 10 ng/ml IL-25, barely splenocytes and macrophage cell lines), splenocytes
from IL-5 transgenic mice (enriched for eosinophils), anddetectable amounts of IL-13 were produced (Figure 5B,
upper panel). Furthermore, the cells producing IL-13 in purified NK1.1CD3 cells were unresponsive to IL-25
(data not shown). As the IL-25-responding cells wereresponse to IL-25 were non-T/non-B cells, as more IL-13
was found in supernatants from cultures containing ei- obviously extremely rare, even in a RAG KO spleen, we
attempted to enrich for these cells by treating RAG KOther WT splenocytes depleted of T and B cells or spleno-
cytes from immunodeficient (RAG KO) mice (Figure 5B, mice with IL-25 in vivo (5 g/day for 4–5 days). The
depletion of CD11b, Gr-1, B220, and CD4 cells fromupper panel). As little as 0.1 ng/ml IL-25 induced the
production of IL-13 protein from RAG KO splenocytes, the spleens of IL-25-treated RAG KO mice resulted in
an enrichment of cells that produced IL-13 (Figure 5B,with optimal stimulation at 10 ng/ml (data not shown).
As similar results were obtained for the production of lower panel) and IL-5 (data not shown). Spleen cells
from IL-25-treated mice were then divided into two pop-IL-5 (data not shown), our results indicate that IL-25
is able to induce the production of at least two Th2- ulations by flow cytometry based on their expression of
MHC class II molecules: class IIlow and class IIhigh. Asassociated cytokines from a non-T/non-B cell popula-
tion. Surprisingly, no IL-4 was detected under these seen in Figure 5B, class IIhigh cells, but not class IIlow cells,
produced significant amounts of IL-13 upon exposureconditions.
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to IL-25. FACS analysis of the IL-25 responders showed intestine (data not shown). No histological changes were
observed in nonmucosal tissues, including the heart,these cells to be MHC class IIhigh, CD11cdull, F4/80low, and
CD4CD8 (Figure 5C and data not shown). thyroid, skeletal muscle, and kidney. Thus, though IL-25
treatment can induce cytokine gene expression in many
different tissues in vivo, only mucosal tissues respondedIL-25 Treatment Induces Pathological Changes
with pathological changes.in the Lung and the Digestive Tract
In addition to hematological changes, we also observed
gross changes in IL-25-treated mice. These changes IL-25 Mediates Its Effects In Vivo through the
Induction of IL-4, IL-5, and IL-13included enlarged stomachs and duodenums that were
full of mucus and bile. Therefore, we microscopically The ability of IL-25 to increase mucus production, serum
IgE, IgG1, and IgA production, and the number of circu-examined multiple tissues from saline and IL-25-treated
animals. In mice treated for 10 days with 5–10 g IL-25, lating eosinophils could be explained by its ability to
induce the expression of IL-4, IL-5, and IL-13. To teststriking histological changes were found in mucosal tis-
sues, including the lungs, esophagus, stomach, small this hypothesis, we looked at the ability of IL-25 to affect
hematopoietic and histological changes in various typesintestine, and large intestine (Figure 6 and data not
shown). of mutant mice. To be able to look at sufficient numbers
of mice over an extended period of time, we infectedIn the lung, the vascular changes were observed in the
medium and small muscular arteries (Figures 6A–6C). mice with an adenoviral construct containing the IL-25
gene (Ad-IL-25). Control mice were infected with theChanges included minimal to moderate medial hypertro-
phy; the presence of eosinophils within the vascular same adenoviral construct lacking the IL-25 gene (Ad-
control). As summarized in Table 1, infection of WT micelumen; and infiltrates of eosinophils and/or mononu-
clear cells beneath the endothelium, within the vessel with Ad-IL-25 resulted in the same changes observed
in WT mice treated with IL-25 protein: eosinophilia, in-wall, and adjacent to the vessel. In contrast to the vascu-
lar changes, which involved more distal vessels, the creased serum Ig, increased gene expression of Th2-
associated cytokines, and pathological changes in mu-changes in the airways were primarily restricted to bron-
chi and larger bronchioles (Figures 6D and 6E). The cosal tissues. Although the histological changes in mice
receiving Ad-IL-25 and IL-25 protein were similar, theepithelium lining the airways was hypertrophied and ap-
peared to contain large amounts of mucus. Periodic findings tended to be more florid in mice receiving Ad-
IL-25, and these changes lasted for up to 30 days postin-acid-Schiff (PAS) and alcian blue stains highlighted the
presence of large amounts of mucus within the lining fection (Figures 6L and 6M). In addition, perivascular
fibrosis was seen in the lungs of mice receiving Ad-IL-epithelium (goblet cells are not usually seen in the
healthy mouse lung). In some mice, mucus filled the 25, but not mice receiving IL-25 protein (data not shown).
Ad-IL-25-infected immunodeficient (RAG KO) miceairway lumina. Epithelial cells also sometimes contained
eosinophilic cytoplasmic inclusions. Eosinophilic, occa- showed the same responses as WT mice, except that
no IL-4 mRNA was detectable in these mice (Table 1).sionally crystalline, material was also observed within
airway lumina and within alveolar macrophages. These data showed that the cells producing IL-5 and
IL-13 in response to IL-25 were neither T nor B cellsIn the digestive tract, epithelial hyperplasia was evi-
dent in the esophagus (Figures 6F and 6G) and nonglan- and are in agreement with our in vitro studies using
lymphoid-deficient splenocytes (Figure 5B).dular stomach. Epithelial cells often contained promi-
nent eosinophilic cytoplasmic inclusions, similar to To determine the roles of IL-4 and IL-13 in the effects
of IL-25 treatment, IL-4R KO mice were infected withthose seen in the respiratory tract epithelium. In the
glandular stomach, vacuolation of epithelial cells in the Ad-IL-25. The IL-4R chain is part of both the IL-4 and
IL-13 receptor complexes (Hilton et al., 1996; Zurawskigastric glands was observed (Figures 6H and 6I), and
eosinophilic cytoplasmic inclusions were seen in pyloric et al., 1995). Interestingly, although the IL-4R KO mice
showed increased mRNA expression of IL-4, IL-5, andepithelial cells. The eosinophilic material in the lungs
and digestive tract did not stain with PAS or alcian blue. IL-13 and developed peripheral blood eosinophilia, they
did not develop any histological changes in the lung orHowever, the vacuolated cells in the glandular stomach
were PAS- and alcian blue-positive, suggesting that they digestive tract (Table 1). Therefore, signaling through
the IL-4R chain is necessary for the development ofwere mucous cells. Inflammatory infiltrates of eosino-
phils, neutrophils, and mononuclear cells were seen in the increased mucus production and epithelial changes,
but not for the development of eosinophilia, in responsethe epithelium and lamina propria of the esophagus and
stomach and sometimes in the submucosa and serosa. to IL-25. To further differentiate the relative contributions
of IL-4 and IL-13 as mediators of the effects of IL-25, weIn the small and large intestines, the goblet cells were
hypertrophied and hyperplastic (Figures 6J and 6K), and infected IL-4 KO and IL-13 KO mice with the adenoviral
constructs. Ad-IL-25-infected IL-4 KO mice had no in-the lumen of the intestines sometimes contained in-
creased mucus. Brunner’s glands in the duodenum were crease in serum IgA, IgE, or IgG1, showing a dependence
on IL-4 gene expression for the production of these Igenlarged and vacuolated. Furthermore, the epithelia of
the large biliary duct in the liver and the large pancreatic isotypes in response to IL-25 (Table 1). Interestingly, Ad-
IL-25-infected IL-4 KO mice did not have any pulmonaryducts were often vacuolated and contained eosinophilic
cytoplasmic inclusions. vascular changes, but did have epithelial changes in the
lungs and GI tract that were equivalent to those seenThe incidence and severity of the changes were dose
related, and as little as 0.1 g IL-25 for 10 days could in WT mice. These results suggest that IL-4 may have
contributed to the pulmonary vascular changes, but notinduce some histological changes in the lungs and small
Immunity
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Figure 6. Microscopic Changes in Mice Receiving 10 g IL-25 Protein for 10 Days or Mice Infected with Ad-IL-25, 30 Days Postinfection
(A–C) Pulmonary changes in mice receiving IL-25 protein (hematoxylin and eosin [H&E]). (A) Vascular changes are localized to medium and
small muscular arteries. The larger muscular artery (*) has no changes, while the smaller branch (arrow) has mild medial hypertrophy and
infiltrates of inflammatory cells (80). (B) Higher magnification of vascular changes in muscular arteries. Numerous eosinophils within the
IL-25 Induces Th2-Associated Responses
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Table 1. IL-13 Mediates the Histological Changes Seen in Mice Infected with Ad-IL-25 Viral Constructs or Infused with IL-25 Protein
Serum Iga Gene ExpressionaBlood Histological
Mice Eosinophilsa IgA IgE IgG1 IL-4 IL-5 IL-13 Changes
WT 11x** 3x** 348x** 8x** 11x* 14x* 525x* present
RAG 1 KO 6x** NA NA NA NC 5x** 172x** present
IL-4R KO 11x** NC NC NC 12x* 31x** 753x** absent
IL-4 KO 10x** NC NC NC NA 12x* 96x* present
IL-13 KO 3x* NC 7x** 5x** 2x* 5x* NA absent
WT  IL-5 mAb NC 3x* 1337x* 17x** 9x** 3x* 14x** present
WT (BALB/c, C57BL/6, and 129 SvEv) mice, C57BL/6 RAG 1 KO mice, BALB/c IL-4R KO, BALB/c IL-4KO mice, and 129 SvEv IL-13KO mice
received i.v. 5  1010 virus particles of either Ad-control or Ad-mIL-25. WT C57BL/6 mice were infused daily with IL-25 protein or saline. IL-
25-treated mice wre also infused weekly with 2 mg of anti-IL-5 mAb or isotype control.
NA, not applicable; NC, no significant change, *p  0.05; **p  0.01.
a Values represent fold increases above Ad-control-treated mice or, for the anti-IL-5 mAb experiment, saline-treated control mice.
to the epithelial changes, observed in mice treated with members of the IL-17 family. The IL-17 gene is ex-
IL-25. IL-13 KO mice that were infected with Ad-IL-25 pressed in activated CD4 T cells and is undetectable
showed increased serum IgE and IgG1, but not IgA, sug- in whole tissues (Fossiez et al., 1998). IL-17 induces
gesting that increased IgA production was dependent splenomegaly due to mobilization of bone marrow pro-
on IL-13 (Table 1). Furthermore, Ad-IL-25-infected IL-13 genitor cells to the spleen and the expansion of neutro-
KO mice did not develop any changes in the lungs or phils (Schwarzenberger et al., 1998). Furthermore, intra-
digestive tract, indicating that the induction of IL-13 by tracheal injections of IL-17 and intraperitoneal injections
IL-25 was critical for the histological changes seen in of IL-17B induce neutrophil recruitment to the lung and
the lungs and the digestive tract. the peritoneum, respectively (Linden et al., 2000; Shi et
As blood eosinophilia was evident in all mutant mouse al., 2000). IL-17, as well as perhaps IL-17B and IL-17C,
strains infected with Ad-IL-25 (Table 1), we tested the mediates its effects on granulopoiesis and inflamma-
dependence of eosinophilia on the induction of IL-5 by tion by the induction of proinflammatory cytokines, such
IL-25. Mice were cotreated with IL-25 protein and either as IL-1, IL-6, GRO, and TNF (Linden et al., 2000;
isotype control mAb or anti-IL-5 mAb. Anti-IL-5 mAb Schwarzenberger et al., 2000; Witowski et al., 2000).
completely abolished the presence of circulating eosin- IL-25, on the other hand, is expressed in activated Th2
ophils in the blood in WT mice that were cotreated with T cells and induces a very different type of inflammatory
5 g/day IL-25 for 10 days (1.7 	 0.8  103 versus 0.0 	 response in vivo.
0.0.  103 eosinophils per l blood in IL-25 protein  Treatment of mice with IL-25 resulted in the induction
isotype control mAb-treated versus IL-25  anti-IL-5
of a different set of cytokine genes compared to IL-17.
mAb-treated mice, respectively; see Table 1). The anti-
Although IL-25 induced a small amount of IL-6 geneIL-5 mAb/IL-25 cotreated mice developed histological
expression, mRNA levels of IL-1, TNF, G-CSF, andchanges that were equivalent to isotype-control-treated
GM-CSF were unchanged. The most significant geneanimals, with the exception that no eosinophilic infiltrate
expression induced in response to IL-25 was IL-4, IL-5,was seen in the analyzed tissues. Anti-IL-5 mAb treat-
and IL-13. Furthermore, treatment of mice with IL-25ment also did not affect the development of increased
resulted in blood eosinophilia and splenomegaly due toserum Ig and cytokine gene expression in response to
the mobilization of hematopoietic progenitors and theIL-25 (Table 1). In summary, the effects of IL-25 treat-
expansion of eosinophils. Increased serum IgE, IgG1,ment in vivo are indirectly mediated through the induc-
and IgA isotypes were found in IL-25-treated mice. Fi-tion of the Th2-associated cytokines IL-4, IL-5, and
nally, exposure to IL-25 caused striking histologicalIL-13.
changes in the lungs and GI tract, including eosinophilic
and mononuclear infiltrates, increased mucus produc-Discussion
tion, and epithelial cell hyperplasia and hypertrophy.
Our results with cytokine-deficient mice clearly showAlthough IL-25 is structurally related to IL-17, its biologi-
cal effects differ dramatically from previously described that the induction of IL-4, IL-5, and IL-13 protein by IL-25
lumen (arrowhead) and beneath the endothelium (arrow) (230). (C) Mononuclear cells and a few eosinophils almost occlude the arterial
lumen.
(D and E) Epithelial changes in the lungs. Proximal airway (*) (periodic acid-Schiff [PAS] stain, 40 [inset 120]). (D) Lung from mouse that
received saline. Inset: higher magnification of bronchiole. (E) Lung from mouse that received IL-25 protein. Intense PAS-positive staining in
the proximal airway epithelium, extending distally to the small arrowheads. Inset: higher magnification of bronchiole.
(F and G) Esophageal changes (H&E, 375). (F) Esophagus from mouse receiving saline. (G) Esophagus from mouse receiving IL-25 protein.
Epithelial hyperplasia with eosinophilic cytoplasmic inclusions (arrow).
(H and I) Stomach changes (H&E, 60). (H) Glandular stomach from mouse receiving saline. (I) Glandular stomach from mouse receiving IL-
25 protein. Vacuolation of mucous cells in the gastric glands.
(J and K) Jejunal changes (alcian blue, 75). (H) Jejunum from mouse receiving saline. (I) Jejunum from mouse receiving IL-25 protein.
Hypertrophy and hyperplasia of goblet cells.
(L and M) Changes in nonglandular stomach (H&E, 60). (L) Nonglandular stomach from mouse receiving Ad-control virus. (M) Nonglandular
stomach from mouse receiving Ad-IL-25. Epithelial hyperplasia and marked hyperkeratosis.
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is responsible for the observed immunologic changes. class II suggests that this cell may be able to present
The increased serum IgE and IgG1 seen in IL-25-treated antigen to T cells. As many different tissues respond
mice was directly due to an increased production of to IL-25 treatment by increased IL-5 and IL-13 gene
IL-4, as Ad-IL-25-infected IL-4-deficient animals did not expression, it is likely that the identified accessory cell
have detectable changes in serum IgE or IgG1. In mice, is widely distributed among different tissues. Further
IL-4 is both necessary and sufficient to promote Ig iso- studies of this cell type, its tissue distribution, and its
typing switching to IgE and IgG1 (Chomarat and Ban- response to IL-25 are currently being pursued. It remains
chereau, 1998; Corry, 1999; Pe`ne et al., 1988). Interest- possible that other cells types may respond to IL-25 by
ingly, elevated serum IgA concentrations were seen in producing Th2 cytokines. Other innate immune cells that
WT mice infected with Ad-IL-25, but not in IL-4 KO or are known to be able to produce IL-5 and/or IL-13 in-
IL-13 KO mice. These data suggest that both IL-4 and clude NK cells, mast cells, eosinophils, and basophils
IL-13 are necessary for IgA production, a result consis- (Chomarat and Banchereau, 1998; Hoshino et al., 1999;
tent with studies by others (Bost et al., 1996; DeKruyff Roboz and Rafii, 1999). Our studies with purified NK
et al., 1993; Yamamoto et al., 1996). The observed blood cells, monocytes, and splenocytes enriched for eosino-
eosinophilia in IL-25-treated mice was directly related phils indicate that they do not produce either IL-5 or
to the induction of IL-5, as anti-IL-5 mAb cotreatment IL-13 in response to IL-25 exposure in vitro. Interest-
effectively suppressed the numbers of circulating eosin- ingly, spleens from WT, but not RAG KO, mice had signif-
ophils as well as eosinophilic infiltrates in the GI tract icantly increased IL-4 gene expression, suggesting that
and the lungs. IL-5 is known to be critical for the differen- T cells and/or B cells were expressing IL-4 mRNA in
tiation and the release of eosinophils from the bone response to IL-25. However, under the in vitro conditions
marrow (Karlen et al., 1998; Roboz and Rafii, 1999). IL- we used, IL-25 failed to induce IL-4 production by un-
25-treated mice also had increased eotaxin gene ex- fractionated WT splenocytes, purified memory or naive
pression. Eotaxin is a key chemokine for the recruitment TCRCD4 T cells, or purified CD19CD11b or
of eosinophils to tissues (Rothenberg, 1999) and may CD19CD11b B cells. Other potential sources of IL-4,
be responsible for the increased presence of eosinophils including TCR T cells and NK-T cells, are currently
in the lungs and GI tract of IL-25-treated mice. As eotaxin under investigation.
gene expression can be induced by IL-4 and IL-13, IL-25 Our studies indicate that IL-25 may be a key cytokine
may not induce eotaxin production directly (Li et al., for the development or the augmentation of Th2-associ-
1999). ated diseases. IL-25 induces MHC class II-expressing
The induction of IL-13 protein expression is the pri- accessory cells to produce IL-5 and IL-13. These IL-25-
mary mediator for the striking histological changes seen responsive cells may ultimately aid in the further devel-
in the lungs and digestive tracts in IL-25-treated animals. opment of the CD4 Th2 cells that are key for the devel-
Only IL-25-treated mice that were deficient in IL-13 or opment of asthma and other allergic reactions, as well as
a component of the IL-13 receptor (IL-4R chain) did antiparasitic responses (Corry, 1999; Romagnani, 1992).
not develop any microscopic changes. IL-13 has been Furthermore, as IL-25-responsive cells are distributed
shown to be necessary for the increased mucus produc- among many different organs, IL-25 may be an impor-
tion and airway hyperresponsiveness that characterize tant mediator of the development of systemic Th2 re-
experimental asthma models (Corry, 1999, Gru¨nig et al., sponses. In humans, for example, there is an association
1998; Wills-Karp et al., 1998). Furthermore, mice with between the development of asthma and other types of
lung-specific transgene expression of IL-13 have a allergies with the influx of eosinophils into the esopha-
histological phenotype similar to the lungs from IL-25- gus (Furuta, 1998; Harding, 1999; Walsh et al., 1999).
treated mice (Zhu et al., 1999). The lungs of pulmonary- Furthermore, a mouse model of experimental esophagi-
IL-13-transgenic mice have mononuclear and eosino- tis shows an influx of eosinophils into the esophagus
philic inflammatory infiltrates, epithelial cell hypertrophy, and the lungs after exposure to a respiratory allergen
greatly increased mucus production, and eosinophilic (Mishra et al., 2001). It is possible that, by producing IL-
crystals. Similar eosinophilic crystals have been pre- 25, localized CD4 Th2 cells could induce systemic Th2
viously reported and may be composed of a T cell- inflammatory responses. Further study of IL-25 will bring
derived eosinophilic chemotactic factor, Ym1 (Ennulat new perspectives on the development of antiparasitic
et al., 1998; Guo et al., 2000). While the local production and allergic responses.
of IL-13 resulted in significant histological changes in
the lungs of transgenic mice, IL-25 treatment induced Experimental Procedures
the systemic production of IL-13, which resulted in
Cloning of Mouse and Human IL-25pathological changes in the GI tract as well as in the
Nested PCR was performed with gene-specific primers and vectorlungs.
primers using a mouse Th2 cDNA library. The sequence of this PCR
Interestingly, RAG KO mice treated with IL-25 had the fragment yielded the 5 end missing in the original clone, and a
same hematological and histological changes as did WT subsequent PCR using 5 primer ATGTACCAGGCTGTTGCATTC
mice. Because IL-25-treated RAG KO mice had increased TTG and 3 primer CTAAGCCATGACCCGGGGCCGCACACACAC
ACA generated the full-length fragment. This method was also usedgene expression of IL-5 and IL-13, it appeared that
to PCR the full-length human fragment. Full-length cDNAs werethere were non-T/non-B cells that responded to IL-25 by
cloned into the TOPO vector (Invitrogen), and the sequence wasproducing Th2-associated cytokines. Our studies with
verified using an ABI 377 or 373 genetic analyzer.RAG KO splenocytes show that the IL-25 responder is
an accessory cell that is MHC class IIhighCD11cdullF4/ Recombinant Adenovirus and Protein Production
80lowCD8CD4. While the role of this accessory cell Using PCR mutagenesis on the IL-25 TOPO template, a BglII site
was introduced using a 5 vector primer CATGATTACGCCAAGCTTin vivo is currently unknown, the high expression of MHC
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GGTACCGAGATCTGATCCACTAGTAACGGCCGCCAGTG and 3 T7 Mice and In Vivo Treatments
C57BL/6, BALB/c, and 129 SvEv wild-type (WT) mice were obtainedvector primer. This PCR product was digested with BglII and EcoRV
and cloned into the BglII- and PmeI-digested adenovirus transfer from Taconic Farms (Germantown, NY) or from a colony maintained
at the DNAX Animal Care Facility. C57BL/6 RAG1-deficient andvector. The vector and recombinant adenovirus production were as
described (Hoek et al., 2000). 5 108 293 cells (Quantum Biotechnol- 129SvEv RAG2-deficient (RAG KO) mice were obtained from either
Jackson (Bar Harbor, ME), Taconic Farms, or from a colony main-ogies Inc., Montreal, Canada) were infected with MOI 10 Ad-IL-
25 in 1 l CMF-1 medium (CellWorks, San Diego, CA) and incubated tained at the DNAX Animal Care Facility. IL-4 KO mice (Ku¨hn et
al., 1991) were backcrossed for 10 generations onto the BALB/cfor 5 days in a cell factory (Nalgen Nunc Int., Naperville, IL). Culture
medium was dialyzed (membrane tubing, MW: 6,000–8,000, Spec- background. IL-4R KO BALB/c mice were a generous gift from Dr.
Frank Brombacher (Noben-Trauth et al., 1997). IL-13 KO 129 Sv/Evtrum Laboratories, Inc., Rancho Dominguez, CA) versus 50 mM Tris-
HCl (pH 8.0), 1 mM EDTA (Buffer A) and passed over HiTrap Q mice were from a colony maintained at the DNAX Animal Care Facil-
ity (McKenzie et al., 1998). Mice were given i.p. 0.1 to 10 g IL-25(Pharmacia, Uppsala, Sweden) to remove virus and many contami-
nating proteins. IL-25 in the flow-through was purified by Heparin protein daily for up to 10 days. For adenovirus infection, mice were
given 5  1010 virus particles intravenously in the tail vein. For co-Sepharose affinity chromatography (Pharmacia) in Buffer A with
NaCl gradient elution. Peak fractions of 
95% pure IL-25 were treatment with mAb, mice were given i.p. 2 mg of either isotype
control mAb or anti-IL-5 (TRFK5) mAb 2 days before the start ofpooled and dialyzed into phosphate-buffered saline and quantified
by PAGE and Coomassie Blue staining using lysozyme as a stan- IL-25 protein injections (5 g/day) and were given another 1 mg of
mAb 7 days later.dard. LPS (endotoxin) levels (1 eu/ml) were determined (BioWhit-
taker Limulus Amebocyte Lysate QCL-1000 pyrogen testing kit,
Walkersville, MD). Blood and Spleen Cell Analyses
Blood was collected in micropipettes, diluted in Haema-Line 2 silos
RNA Isolation and Quantification of mRNA Expression (BioChem ImmunoSystems, Allentown, PA), and run on a blood
For the determination of IL-25 gene expression in cell lines, pre- analyzer, System 9010 CP (Serono-Baker Diagnostics, Allentown,
viously described cDNA libraries were used (Halfon et al., 1998). For PA), which gives the total white blood cell count per mouse. Blood
quantification of IL-25 and other cytokines in whole mouse tissues, smears were made concurrently. Individual mouse spleens were
total RNA was isolated from whole tissues using Qiagen Rneasy made into single-cell suspension, counted by hemocytometer, and
columns (Qiagen, Valencia, CA) according to the manufacturer’s then an aliquot was used for a cytospin. Both splenic cytospins and
instructions. Total RNA (5 g) was treated with DNase I to remove blood smears were stained with Wright’s stain and modified Giemsa
any contaminating genomic DNA (Ambion, Austin, TX) and then stain (Sigma Diagnostics, St. Louis, MO) and counted to determine
reverse transcribed into cDNA using random hexamers (Promega, relative percentage of mononuclear cells, neutrophils, and eosino-
Madison, WI). Then gene expression was determined by a method phils. Absolute numbers of each cell type were then calculated for
for real-time quantitative PCR using the ABI 7700 sequence detector individual mice.
system (Perkin Elmer Applied Biosystems, Foster City, CA). Briefly,
50 ng total cDNA was in a reaction volume of 25 l that contained Determination of Serum Ig Isotypes
final concentrations of 1 PCR buffer, 200 M dATP, dCTP, dGTP, Serum Ig was determined either after 10 days of treatment with
and 400 M dUTP, 4 mM MgCl2, 1.25 U AmpliTaq DNA polymerase, saline or IL-25 protein or 14 days after infection with Ad-control or
0.5 U Amp-Erase uracil-N-glycocylase, 900 nM of each primer, and Ad-IL-25. IgA from intestinal contents (fecal matter) was determined
250 nM probe. The thermal cycling conditions included 50C for 2 after 20 days of treatment with either saline or 5g/day IL-25 protein.
min and 95C for 10 min, followed by 40 cycles of amplification at IgG1 and IgG2a were determined using specific capture and detection95C for 15 s and 60C for 1 min for denaturing and anneal extension, antibody pairs (Southern Biotechnology Associates, Birmingham,
respectively. For relative quantification of the expression of IL-25 AL), followed by incubation with streptavidin-horse peroxidase
mRNA, primers 5CGGAGGAGTGGCTGAAGTGGAG and 5ATGGG (Jackson ImmunoResearch Labs, West Grove, PA). IgA was cap-
TACCTTCCTCGCCATG were used in a reaction mix containing tured with rat anti-mouse IgA (PharMingen, San Diego, CA) and
20 ng (cell line cDNA libraries) or 50 ng (whole tissues) cDNA detected with NIP-conjugated 2740C. IgE levels were determined
with a reporter fluorescent dye, SYBR. PCR amplification of the using the antibody pairs EM95 and NIP-conjugated 210E. IgA and
housekeeping gene ubiquitin was performed for each sample to
IgE plates were then incubated with J4-anti-NIP peroxidase. The
control for sample loading and to allow normalization between sam-
peroxidase reaction was developed with TMB Microwell Peroxidase
ples according to the manufacturer’s instructions (Perkin Elmer).
Substrate (Kirkegaard & Perry Laboratories, Gaithersburg, MD) and
Sense and antisense primers, as well as probes used for the detec-
stopped with 1 M phosphoric acid. Plates were read on a plate
tion of all other genes of interest, were predeveloped TaqMan assay
reader at 450 nm.
reagents (Perkin Elmer). Primers and probes were designed to en-
sure that no cross-reactivity with other genes would occur. The
In Vitro Cytokine Production Assayprobes for each message were labeled at the 5 end with a reporter
Single-cell suspension was made from C57BL/6 WT (Figure 5B,fluorescent dye, FAM, and at the 3 end with a quench fluorescent
upper panel), C57BL/6 RAG 1 KO (unfractionated and depletiondye, TAMRA. Fluorescence detection of FAM was performed at the
studies; Figure 5B, upper and lower panel), and 129 SvEv RAG 2end of each cycle. The quantity of cDNA of the gene of interest was
KO (cell sorting; Figure 5B, lower panel, Figure 5C) spleens. Reddirectly related to the amount of FAM detected after 40 cycles. For
blood cells were lysed with a NaCl gradient. To deplete WT spleno-quantification of the expression of various cytokine and chemokine
cytes of T and B cells, cells were incubated with anti-CD4, anti-mRNA, cDNA plasmids containing the gene of interest were used
CD8, and anti-B220 mAb supernatants (10% v/v), then mixed withas a standard curve, ranging from 100 to 0.01 pg. From this standard
goat anti-rat IgG (Fc)-coated and goat anti-rat IgG (HL)-coatedcurve, the amount of cDNA of the gene of interest was calculated
magnetic beads (PerSeptive Diagnostics, Cambridge, MA), and thein fg/50 ng total cDNA. As internal control, 18S rRNA expression
positive cells were removed magnetically. Cells were plated at 105was measured in each sample in a multiplex assay; the probe for
cells per well in triplicate with or without IL-25 in a 96-well U-bottomrRNA was labeled at the 5 end with the reporter fluorescent dye
microtiter plate in RPMI 1640  10% heat inactivated fetal bovineVIC. The amount of 18S rRNA was correlated with the cycle at which
serum supplemented with 2 mM L-glutamine, 50M 2-mercaptoeth-VIC fluorescence was first detected (cycle threshold value). In order
anol, 100 U/ml penicillin, 100 g/ml streptomycin, 10 mM HEPES,to correct for any variation in the amount of RNA between individual
and 1 mM sodium pyruvate. Cell-free supernatants were collectedsamples, the mean cycle threshold value for 18S rRNA was calcu-
after 72 hr and assayed for IL-13 by ELISA. IL-13 was detected usinglated for all samples, subtracted from each individual cycle threshold
the Quantikine M mouse IL-13 Immunoassay kit (R&D Systems, Inc.,value, and then this difference was raised to the second power and
Minneapolis, MN) in accordance with the manufacturer’s instruc-multiplied by the FAM value (in fg/50 ng total cDNA) for each sample.
tions. To deplete RAG splenocytes of granulocytes and myeloidThus the amount of cDNA of the gene of interest in each sample
cells, the cells were incubated with anti-CD4, anti-B220, anti-Gr-1,could be directly compared to amounts detected in all other
samples. and anti-CD11b mAb supernatants, positive cells were removed
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using magnetic beads, and the remaining cells were cultured as Wilson, T. (1996). Cloning and characterization of a binding subunit
of the interleukin 13 receptor that is also a component of the interleu-described above. For sorting cells based on MHC class II expres-
sion, spleens were taken from RAG KO mice that had been treated kin 4 receptor. Proc. Natl. Acad. Sci. USA 93, 497–501.
for 4–5 days with 5 g IL-25. The splenocytes were stained with Hoek, R.M., Ruuls, S.R., Murphy, C.A., Wright, G.J., Goddard, R.,
anti-I-Ab and anti-CD11c mAbs (both from PharMingen), sorted on Zurawski, S.M., Blom, B., Homola, M.E., Streit, W.J., Brown, M.H.,
a FACS Vantage SE (Becton-Dickinson, Mountain View, CA) based et al. (2000). Down-regulation of the macrophage lineage through
on their MHC class II expression (
95% purity), and then cultured interaction with OX2 (CD200). Science 290, 1768–1771.
as described above. After sorting, some MHC class IIhigh cells were
Hoshino, T., Winkler-Pickett, R.T., Mason, A.T., Ortaldo, J.R., and
further stained with anti-CD8 mAb (PharMingen) for further FACS
Young, H.A. (1999). IL-13 production by NK cells: IL-13-producing
analysis.
NK and T cells are present in vivo in the absence of IFN-. J. Immu-
nol. 162, 51–59.
Histologic Analyses
Jovanovic, D.V., Di Battista, J.A., Martel-Pelletier, J., Jolicoeur, F.C.,Microscopic examination of mouse tissues was performed in a
He, Y., Zhang, M., Mineau, F., and Pelletier, J.P. (1998). IL-17 stimu-blinded fashion by the same pathologist (M.W. Leach) on formalin-
lates the production and expression of proinflammatory cytokines,fixed tissue sections stained with either hematoxylin and eosin
IL-1beta and TNF-alpha, by human macrophages. J. Immunol. 160,(H&E), periodic acid-Schiff (PAS), or alcian blue.
3513–3521.
Karlen, S., De Boer, M.L., Lipscombe, R.J., Lutz, W., Mordvinov,Statistics
V.A., and Sanderson, C.J. (1998). Biological and molecular charac-All data were analyzed using a statistical program (InstatP). A Stu-
teristics of interleukin-5 and its receptor. Int. Rev. Immunol. 16,dent’s t test or a nonparametric Mann-Whitney test was used to
227–247.determine statistical significance between groups, with p  0.05
being considered significant. Ku¨hn, R., Rajewsky, K., and Mu¨ller, W. (1991). Generation and analy-
sis of interleukin-4 deficient mice. Science 254, 707–710.
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